Jeffrey S Dome

List of Publications by Year
in descending order

148 papers	7,458 citations	36271 51 h-index	60583 81 g-index
159 all docs	159 docs citations	159 times ranked	6124 citing authors

#	Article	IF	Citations
1	Recurrent Respiratory Papillomatosis With Complete Response to Systemic Bevacizumab Therapy. Ear, Nose and Throat Journal, 2024, 103, 100-101.	0.4	1
2	Renal tumors. , 2022, , 525-540.		0
3	ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosisâ€"A Report from the Childrenâ€™s Oncology Group Study AREN0534. Annals of Surgical Oncology, 2022, , 1.	0.7	1
4	Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Childrenâ€™s Oncology Group Study AREN0534. Annals of Surgical Oncology, 2022, 29, 3252-3261.	0.7	8
5	Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. Supportive Care in Cancer, 2022, 30, 3513-3520.	1.0	4
6	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 2022, 6, 2520-2534.	2.5	19
7	White paper: Oncoâ€fertility in pediatric patients with Wilms tumor. International Journal of Cancer, 2022, , .	2.3	5
8	Authorsâ€™ Reply to the Letter to the Editor by Daniel M. Green. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, xlvii-xlviii.	2.3	0
9	Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). Cancer, 2022, 128, 2493-2503.	2.0	6
10	MP17-16â€ƒLONG-TERM OUTCOMES FOR PATIENTS WITH ANAPLASTIC BILATERAL WILMS TUMORS ENROLLED ON COG AREN0534. Journal of Urology, 2022, 207, .	0.2	0
11	Revisiting the Threshold for Cancer Genetics Referral in Patients With Wilms Tumor. Journal of Clinical Oncology, 2022, 40, 1853-1860.	0.8	5
12	Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. Journal of Clinical Oncology, 2022, 40, 3047-3056.	0.8	19
13	Wilms Tumor. , 2021, , 139-162.		0
14	Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in the Washington Metropolitan Area as of October 2020. Pediatric Infectious Disease Journal, 2021, 40, e272-e274.	1.1	7
15	Targeting the HIF-1Î±-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. Oncogene, 2021, 40, 4809-4819.	2.6	12
16	Impact of the First Generation of Childrenâ€™s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 978-985.	2.3	26
17	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	0.8	3
18	New approaches to risk stratification for Wilms tumor. Current Opinion in Pediatrics, 2021, 33, 40-48.	1.0	36

#	Article	IF	Citations
19	Outcome of Donor-Derived Tumor Associated Antigen-Specific T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT. Blood, 2021, 138, 2828-2828.	0.6	2
20	Pediatric Solid Tumors. , 2020, , 1703-1747.e11.		7
21	Summary of COVIDâ€19 clinical practice adjustments across select institutions. Pediatric Blood and Cancer, 2020, 67, e28411.	0.8	4
22	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcomaâ€"A Children's Oncology Group study. Cancer, 2020, 126, 5303-5310.	2.0	17
23	A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group ARENO321 study. Cancer, 2020, 126, 5156-5164.	2.0	19
24	Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer, 2020, 126, 3516-3525.	2.0	45
25	Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2. American Journal of Roentgenology, 2020, 214, 987-994.	1.0	28
26	Outcome analysis of stage I epithelialâ€predominant favorableâ€histology Wilms tumors: A report from Children's Oncology Group study AREN03B2. Cancer, 2020, 126, 2866-2871.	2.0	20
27	Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Childrenâ€™s Oncology Group AREN0321 Study. Journal of Clinical Oncology, 2020, 38, 1558-1568.	0.8	50
28	Reply to D.M. Green. Journal of Clinical Oncology, 2020, 38, 773-774.	0.8	1
29	BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. Journal of Physical Education and Sports Management, 2020, 6, a004820.	0.5	4
30	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. Journal of Pediatrics, 2020, 223, 183-185.	0.9	15
31	414â€...Enhancing T cell therapy for patients with relapsed/refractory Wilms tumor. , 2020, , .		0
32	Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. Journal of Clinical Oncology, 2019, 37, 2349-2359.	0.8	56
33	Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. European Journal of Cancer, 2019, 118, 58-66.	1.3	32
34	Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Childrenâ€™s Oncology Group AREN0532 and AREN0533 Study Report. Journal of Clinical Oncology, 2019, 37, 2769-2777.	0.8	44
35	Reply to L. Xie et al. Journal of Clinical Oncology, 2019, 37, 1264-1265.	0.8	0
36	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nature Communications, 2019, 10, 5806.	5.8	27

#	Article	IF	Citations
37	Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1â€5: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27430.	0.8	12
38	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	0.9	60
39	Wilms Tumor-Nephroblastoma. , 2019, , 11-29.		1
40	Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilmsâ€™ tumor. JCI Insight, 2019, 4, .	2.3	21
41	Reply to B. Zhang et al. Journal of Clinical Oncology, 2018, 36, 1454-1455.	0.8	0
42	Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Childrenâ€™s Oncology Group AREN0533 Study. Journal of Clinical Oncology, 2018, 36, 1564-1570.	0.8	87
43	Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2018, 36, 3396-3403.	0.8	37
44	Reply to D.M. Green. Journal of Clinical Oncology, 2018, 36, 3179-3181.	0.8	1
45	A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Childrenâ€™s Oncology Group study. PLoS ONE, 2018, 13, e0208936.	1.1	35
46	Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group Study AREN0532. Journal of Clinical Oncology, 2018, 36, 254-261.	0.8	78
47	The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer, 2018, 124, 3381-3389.	2.0	72
48	A prospective study of pediatric renal cell carcinoma: A report from the Childrenâ€™s Oncology Group study AREN0321.. Journal of Clinical Oncology, 2018, 36, 10516-10516.	0.8	4
49	Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. Pediatric Blood and Cancer, 2017, 64, e26406.	0.8	6
50	Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor. Annals of Surgery, 2017, 265, 835-840.	2.1	77
51	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nature Genetics, 2017, 49, 1487-1494.	9.4	255
52	Imaging of renal medullary carcinoma in children and young adults: a report from the Childrenâ€™s Oncology Group. Pediatric Radiology, 2017, 47, 1615-1621.	1.1	17
53	Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor. Journal of Pediatric Surgery, 2017, 52, 98-103.	0.8	11
54	Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1905-1910.	0.8	39

#	Article	IF	Citations
55	Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 5582-5591.	3.2	82
56	Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2016, 34, 3189-3194.	0.8	117
57	Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. Human Pathology, 2016, 48, 81-87.	1.1	33
58	Safety and feasibility of magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) for the ablation of relapsed or refractory pediatric solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS10588-TPS10588.	0.8	0
59	Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. Cancer, 2015, 121, 2457-2464.	2.0	92
60	Overall Survival and Renal Function of Patients With Synchronous Bilateral Wilms Tumor Undergoing Surgery at a Single Institution. Annals of Surgery, 2015, 262, 570-576.	2.1	52
61	Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor. Pediatric Blood and Cancer, 2015, 62, 1075-1077.	0.8	6
62	MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nature Communications, 2015, 6, 10013.	5.8	64
63	Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. Cancer Cell, 2015, 27, 286-297.	7.7	244
64	Reply to Wilms tumor and breast cancer. Cancer, 2015, 121, 2100-2101.	2.0	0
65	The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer Biology and Therapy, 2015, 16, 949-957.	1.5	24
66	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. Journal of Clinical Oncology, 2015, 33, 2999-3007.	0.8	281
67	Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Childrenâ€™s Oncology Group. Pediatric Radiology, 2015, 45, 166-172.	1.1	45
68	Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Childrenâ€™s Oncology Group (COG) study AREN0532.. Journal of Clinical Oncology, 2015, 33, 10010-10010.	0.8	2
69	Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Childrenâ€™s Oncology Group study AREN0533.. Journal of Clinical Oncology, 2015, 33, 10011-10011.	0.8	17
70	Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Childrenâ€™s Oncology Group AREN0532.. Journal of Clinical Oncology, 2015, 33, 10023-10023.	0.8	3
71	TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia. PLoS ONE, 2014, 9, e109924.	1.1	82
72	Risk Stratification for Wilms Tumor: Current Approach and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 215-223.	1.8	124

#	Article	IF	Citations
73	DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Modern Pathology, 2014, 27, 1267-1280.	2.9	153
74	Breast cancer in Wilms tumor survivors: New insights into primary and secondary prevention. Cancer, 2014, 120, 3598-3601.	2.0	2
75	Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. Cancer Genetics, 2014, 207, 403-411.	0.2	13
76	Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group. Pediatric Blood and Cancer, 2014, 61, 134-139.	0.8	39
77	Repeat nephron-sparing surgery for children with bilateral Wilms tumor. Journal of Pediatric Surgery, 2014, 49, 149-153.	0.8	30
78	Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. Journal of Pediatric Urology, 2014, 10, 969-973.	0.6	6
79	Aberrant activation, nuclear localization, and phosphorylation of yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatric Blood and Cancer, 2014, 61, 198-205.	0.8	32
80	Real-time central review: A report of the first 3,000 patients enrolled on the Childrenâ€™s Oncology Group Renal Tumor Biology and Risk Stratification protocol AREN03B2.. Journal of Clinical Oncology, 2014, 32, 10000-10000.	0.8	8
81	Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Childrenâ€™s Oncology Group study AREN0533.. Journal of Clinical Oncology, 2014, 32, 10001-10001.	0.8	16
82	A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Childrenâ€™s Oncology Group AREN0321 study.. Journal of Clinical Oncology, 2014, 32, 10032-10032.	0.8	12
83	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 10052-10052.	0.8	1
84	Primary nephrectomy and intraoperative tumor spill: Report from the Children's Oncology Group (COG) renal tumors committee. Journal of Pediatric Surgery, 2013, 48, 34-38.	0.8	62
85	Gain of 1q is associated with inferior eventâ€free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. Cancer, 2013, 119, 3887-3894.	2.0	82
86	Children's Oncology Group's 2013 blueprint for research: Renal tumors. Pediatric Blood and Cancer, 2013, 60, 994-1000.	0.8	140
87	Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor. Journal of Pediatric Surgery, 2013, 48, 1481-1485.	0.8	30
88	Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Childrenâ€™s Oncology Group. Journal of Pediatric Surgery, 2013, 48, 1598-1603.	0.8	26
89	Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Childrenâ€™s Oncology Group. Radiology, 2013, 266, 610-617.	3.6	51
90	Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor. Journal of Clinical Oncology, 2013, 31, 1196-1201.	0.8	78

#	Article	IF	Citations
91	Prognostic implications of gain of 1q in favorable histology Wilms tumor: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2013, 31, 10014-10014.	0.8	0
92	A genome-wide association study identifies susceptibility loci for Wilms tumor. Nature Genetics, 2012, 44, 681-684.	9.4	72
93	Clinically Relevant Subsets Identified by Gene Expression Patterns Support a Revised Ontogenic Model of Wilms Tumor: A Children's Oncology Group Study. Neoplasia, 2012, 14, 742-IN21.	2.3	105
94	Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. Journal of Pediatric Surgery, 2012, 47, 700-706.	0.8	83
95	Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization. PLoS ONE, 2012, 7, e52397.	1.1	138
96	Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 58, 551-555.	0.8	65
97	Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studiesâ€4 and â€5: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 631-635.	0.8	71
98	Strategy for management of retroperitoneal tumors with caval tumor thrombus. Journal of Pediatric Surgery, 2011, 46, 2065-2070.	0.8	23
99	Barriers to the Enrollment of Children in the Children's Oncology Group Study of Very Low Risk Wilms Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, 521-523.	0.3	8
100	Molecular profiling reveals frequent gain of MYCN and anaplasiaâ€specific loss of 4q and 14q in wilms tumor. Genes Chromosomes and Cancer, 2011, 50, 982-995.	1.5	54
101	WT1 Mutation and 11P15 Loss of Heterozygosity Predict Relapse in Very Low-Risk Wilms Tumors Treated With Surgery Alone: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 698-703.	0.8	75
102	Reply to B. Royer-Pokora et al. Journal of Clinical Oncology, 2011, 29, e487-e488.	0.8	0
103	Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prevention Research, 2011, 4, 1973-1981.	0.7	37
104	Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group. Clinical Cancer Research, 2009, 15, 1770-1778.	3.2	59
105	Subsets of Very Low Risk Wilms Tumor Show Distinctive Gene Expression, Histologic, and Clinical Features. Clinical Cancer Research, 2009, 15, 6800-6809.	3.2	51
106	Loss of Heterozygosity at 2q37 in Sporadic Wilms' Tumor: Putative Role for miR-562. Clinical Cancer Research, 2009, 15, 5985-5992.	3.2	56
107	Anthropomorphic measurements and eventâ€free survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2009, 52, 254-258.	0.8	10
108	Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatric Blood and Cancer, 2009, 52, 430-430.	0.8	12

#	Article	IF	Citations
109	Treatment of relapsed Wilms tumors: lessons learned. Expert Review of Anticancer Therapy, 2009, 9, 1807-1815.	1.1	77
110	Hepatic Metastasis at Diagnosis in Patients With Wilms Tumor is not an Independent Adverse Prognostic Factor for Stage IV Wilms Tumor. Annals of Surgery, 2009, 250, 642-648.	2.1	48
111	Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatric Radiology, 2008, 38, 2-17.	1.1	140
112	The feasibility and outcome of nephronâ€sparing surgery for children with bilateral Wilms tumor. Cancer, 2008, 112, 2060-2070.	2.0	125
113	Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatric Blood and Cancer, 2008, 50, 246-249.	0.8	40
114	Current and Emerging Chemotherapy Treatment Strategies for Wilms Tumor in North America. Paediatric Drugs, 2008, 10, 115-124.	1.3	22
115	Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research, 2008, 14, 4572-4583.	3.2	116
116	ELR+-CXC Chemokines and Their Receptors in Early Metanephric Development. Journal of the American Society of Nephrology: JASN, 2007, 18, 2359-2370.	3.0	19
117	Topotecan Is Active Against Wilmsâ€™ Tumor: Results of a Multi-Institutional Phase II Study. Journal of Clinical Oncology, 2007, 25, 3130-3136.	0.8	60
118	Telomere Biology of Pediatric Cancer. Cancer Investigation, 2007, 25, 197-208.	0.6	17
119	Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. Genes Chromosomes and Cancer, 2007, 46, 607-615.	1.5	19
120	Significance of pleural effusion in neuroblastoma. Pediatric Blood and Cancer, 2007, 49, 906-908.	0.8	15
121	Treatment of Stage IV Malignant Rhabdoid Tumor of the Kidney (MRTK) With ICE and VDCy. Journal of Pediatric Hematology/Oncology, 2006, 28, 286-289.	0.3	26
122	Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatric Blood and Cancer, 2006, 46, 527-527.	0.8	7
123	Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors. Clinical Cancer Research, 2006, 12, 7284-7293.	3.2	52
124	Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study. Journal of Clinical Oncology, 2006, 24, 2352-2358.	0.8	290
125	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2006, 24, 563-570.	0.8	70
126	Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with Relapse. Cancer Research, 2006, 66, 11148-11155.	0.4	47

#	Article	IF	Citations
127	Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor. Journal of Clinical Oncology, 2005, 23, 7641-7645.	0.8	227
128	Current Therapy for Wilmsâ€™ Tumor. Oncologist, 2005, 10, 815-826.	1.9	179
129	High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor. Journal of Clinical Oncology, 2005, 23, 9138-9145.	0.8	61
130	Disappearance of the Telomere Dysfunction-Induced Stress Response in Fully Senescent Cells. Cancer Research, 2004, 64, 3748-3752.	0.4	71
131	Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma. Journal of Clinical Oncology, 2004, 22, 3790-3797.	0.8	90
132	Significance of pleural effusion at diagnosis of Wilms tumor. Pediatric Blood and Cancer, 2004, 42, 145-148.	0.8	9
133	Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer, 2004, 101, 1575-1583.	2.0	152
134	Management of Wilms' tumour: current practice and future goals. Lancet Oncology, The, 2004, 5, 37-46.	5.1	167
135	Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genetics and Cytogenetics, 2003, 141, 97-105.	1.0	81
136	Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer, 2003, 97, 2318-2326.	2.0	30
137	Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. British Journal of Haematology, 2003, 120, 846-849.	1.2	118
138	Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clinical Cancer Research, 2003, 9, 5442-53.	3.2	135
139	Improved Survival for Patients With Recurrent Wilms Tumor: The Experience at St. Jude Children's Research Hospital. Journal of Pediatric Hematology/Oncology, 2002, 24, 192-198.	0.3	104
140	Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide. Journal of Pediatric Hematology/Oncology, 2002, 24, 250-255.	0.3	35
141	Recent advances in Wilms tumor genetics. Current Opinion in Pediatrics, 2002, 14, 5-11.	1.0	135
142	Complete Response of Recurrent Cellular Congenital Mesoblastic Nephroma to Chemotherapy. Journal of Pediatric Hematology/Oncology, 2002, 24, 478-481.	0.3	45
143	Treatment of Metastatic Rhabdoid Tumor of the Kidney. Journal of Pediatric Hematology/Oncology, 2002, 24, 385-388.	0.3	59
144	Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene, 2002, 21, 6694-6702.	2.6	165

#	Article	IF	Citations
145	Intraatrial and intracaval Wilms' tumor. Journal of Pediatric Surgery, 2001, 36, 1869-1871.	0.8	2
146	Telomerase Activity and Prognosis in Primary Breast Cancers. Journal of Clinical Oncology, 1999, 17, 3075-3081.	0.8	52
147	Three molecular determinants of malignant conversion and their potential as therapeutic targets. Current Opinion in Oncology, 1999, 11, 58.	1.1	5
148	Incorporation of fluorescently labeled actin and tropomyosin into muscle cells. Cell Differentiation, 1988, 23, 37-52.	1.3	35